---
title: "Weekly Recap | Aytu BioPharma +7.55%, earnings beat estimates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300187014.md"
description: "Aytu BioPharma gained 7.55% this week to close at $2.28, while the S&P 500 rose 1.21%, leaving the stock roughly 6.34 percentage points ahead of the benchmark. The week began with a dip on Monday (21 Sep), when shares touched an intraday low of $2.10. Buying picked up on Tuesday (22 Sep) with a sharp intraday swing of nearly 9%. Wednesday (23 Sep) saw the high of $2.35 before a pullback, with Thursday and Friday settling into a tight range near $2.28."
datetime: "2026-09-26T06:06:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300187014.md)
  - [en](https://longbridge.com/en/news/300187014.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300187014.md)
generator: "portal-rs"
---

# Weekly Recap | Aytu BioPharma +7.55%, earnings beat estimates

## The Week

Aytu BioPharma gained 7.55% this week to close at $2.28, while the S&P 500 rose 1.21%, leaving the stock roughly 6.34 percentage points ahead of the benchmark. The week began with a dip on Monday (21 Sep), when shares touched an intraday low of $2.10. Buying picked up on Tuesday (22 Sep) with a sharp intraday swing of nearly 9%. Wednesday (23 Sep) saw the high of $2.35 before a pullback, with Thursday and Friday settling into a tight range near $2.28. Daily volume averaged about 123k shares, more than four times the trailing median.\\n\\n## Key Events\\n\\nThe main story was the fiscal Q4 2026 earnings report on 23 Sep. GAAP EPS came in at $0.00, beating estimates by $0.33, while quarterly revenue of $16.1 million beat by $3.82 million. The EXXUA launch drove the CNS therapeutics segment to $6.6 million in revenue. On a full-year basis, total sales fell 13% and net loss reached $14.3 million; the narrower quarterly net loss narrowed to $15,000, with revenue up 6.4% year on year. The 10-K showed fiscal 2026 revenue of $57.57 million and EPS of negative $1.16. The earnings call focused on EXXUA growth and the FY2027 outlook.\\n\\n## Analyst Ratings\\n\\nThree brokers cover the name: two rate it buy and one rates it overweight, with no hold, underweight or sell ratings. The consensus rating is strong buy, with a consensus target of $9.50, about 317% above the latest price. Individual targets range from $7.00 to $14.50, indicating wide dispersion. Within the pharmaceutical industry, the stock ranks 128th out of 203 covered names, in the lower half.\\n\\n## The Week Ahead\\n\\nBeyond the earnings aftermath, next week brings a heavier macro calendar. On Monday (28 Sep) the Dallas Fed manufacturing business activity index is due. Tuesday (29 Sep) features FHFA house prices, Case Shiller home price indices, JOLTS job openings and consumer confidence. No fresh company earnings are scheduled; the key watch items are EXXUA sales momentum and how the FY2027 guidance holds up.\\n\\n## In Short\\n\\nThis week paired a strong price move with upbeat earnings, and broker ratings lean positive with a consensus target far above spot. Yet coverage is thin and target dispersion is wide. The price-to-book sits around 0.7x, below net asset value; the latest session’s flow data shows net inflows from medium and small orders. What matters next is whether EXXUA revenue carries into the coming quarter and how macro data weighs on sentiment.\\n\\n*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [AYTU.US](https://longbridge.com/en/quote/AYTU.US.md)

## Related News & Research

- [Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales](https://longbridge.com/en/news/299809035.md)
- [AYTU: EXXUA launch drives growth in CNS therapeutics, with FY26 revenue at $66.4M](https://longbridge.com/en/news/299813775.md)
- [Time to Nibble on MCD Stock After it Enters Oversold Territory?](https://longbridge.com/en/news/300812314.md)
- [2 of the Best Warren Buffett Stocks for a Lifetime of Passive Income](https://longbridge.com/en/news/300803278.md)
- [Cathie Wood Is Buying Rocket Lab Again: Why 3 ARK ETFs Are Betting on Neutron](https://longbridge.com/en/news/300816393.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**